|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01810744 |
|
Date of registration:
|
12/03/2013 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma
BEVACAPI |
|
Scientific title:
|
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma |
|
Date of first enrolment:
|
May 2013 |
|
Target sample size:
|
47 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01810744 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
France
| | | | | | | |
|
Contacts
|
|
Name:
|
François Ghiringhelli, Professor |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Centre Georges Francois Leclerc |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age = 18 years
- signed informed Consent
- Medical Examination
- Patients with metastatic colorectal cancer
- Patients with a glioblastoma
- patient to receive treatment with bevacizumab not yet started
- MRI for patients with glioblastoma or scanner TAP for patients carrying a metastatic
colon cancer performed within 3 weeks before inclusion.
Exclusion Criteria:
- Bevacizumab already initiated or history of antiangiogenic treatment
- Inability legal (persons deprived of liberty or under guardianship)
- Pregnant or lactating women
- Can not sign consent or unable to undergo medical follow up for geographical, social
or psychological reasons
- Patients not covered by Medicare including CMU
- Estimated life of over 3 months
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Glioblastoma
|
|
Bevacizumab
|
|
Capillaroscopy
|
|
Metastatic Colorectal Cancer
|
|
Intervention(s)
|
|
Other: blood pressure measurement
|
|
Other: capillaroscopy
|
|
Primary Outcome(s)
|
|
change in the density of capillaries
[Time Frame: baseline and after 15 days of bevacizumab treatment]
|
|
Secondary ID(s)
|
|
001-FANI-2012
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|